SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Rocket Lab Corp. engages in the development of rocket launch and control systems for the space and defense industries. It operates through the Launch Services and Space Systems segments. The Launch Services segment provides launch services to customers on a dedicated mission or ride-share basis. The Space Systems segment consists of spacecraft engineering and design services, spacecraft components, spacecraft manufacturing, and on-orbit mission operations. The company was founded by Peter Beck in 2006 and is headquartered in Long Beach, CA.

Rocket Lab Corp.

Rocket Lab USA Inc

Rocket Lab is experiencing high volatility as investors weigh record revenue and a massive backlog against an EPS miss and concerns surrounding the Neutron rocket development schedule. The community is sharply divided, with bulls pointing to the company's strong growth and strategic expansion while skeptical traders focus on valuation concerns and the risks of further development delays.

XRP is a decentralized digital asset and the native token of the XRP Ledger, a Layer 1 blockchain designed for high-performance global payments. Its primary value proposition is offering a fast, cost-effective alternative to traditional banking systems by enabling near-instant cross-border settlements that finalize in three to five seconds. By serving as a neutral bridge asset between different fiat currencies, it helps financial institutions lower liquidity costs and eliminates the need for pre-funded accounts.  The network is unique because it utilizes a federated consensus protocol instead of energy-intensive mining or staking. This system achieves deterministic finality through a Unique Node List of trusted validators who must reach an eighty percent agreement threshold to permanently record transactions. This infrastructure supports a sustained throughput of 1,500 transactions per second and includes a built-in decentralized exchange that allows for the automated trading of any tokenized asset without intermediaries.  The project traces its origins back to 2004 with Ryan Fugger before being co-founded in its modern form by Jed McCaleb and Chris Larsen. The company, now known as Ripple, works with major financial institutions as partners and investors to build global payment solutions. To protect the network from spam, a small amount of XRP is burned during every transaction, and the token is further utilized by institutions as collateral to access traditional markets and manage digital asset infrastructure.  Institutional adoption of the asset reached a major milestone in November 2025 when the SEC approved the first wave of spot XRP ETFs. These products, offered by major issuers including Bitwise, Grayscale, 21Shares, Canary Capital, and Franklin Templeton, are now listed on prominent exchanges like the NYSE Arca, Nasdaq, and Cboe BZX. While Ripple remains a key contributor to the ecosystem, the underlying XRP Ledger continues to operate as an open-source and decentralized network.

Ripple

XRP is trending amid intense debate over the stalled Clarity Act, with community members polarized between those viewing the current price consolidation as a strategic accumulation opportunity and those concerned that the asset has lost utility momentum. Discussions are dominated by speculation regarding potential support levels near the one-dollar mark, as traders weigh regulatory uncertainty against the long-term infrastructure narrative.

Fermi, Inc. engages in the development of energy infrastructure. It intends to develop an energy and data center development campus to support the needs of to-be-built AI infrastructure. The company was founded by Rick Perry, Toby Neugebauer and Griffin Perry on January 10, 2025 and is headquartered in Amrillo, TX.

Fermi Inc

Fermi LLC

Fermi is trending following the announcement of a massive binding lease agreement with TensorWave for its Project Matador facility, which is expected to generate significant long-term contracted revenue. Community members are actively speculating that a 'global leader in AI' is backstopping the deal, sparking heated debate over the companys ability to secure additional hyperscale tenants and validate its large-scale power infrastructure.

Redwire Corp. engages in the development and provision of space and defense technologies and mission-critical solutions for government, commercial, and civil customers. Its offerings include spacecraft platforms, space infrastructure, avionics, sensors and payloads, power generation systems, radio frequency systems, microgravity research and manufacturing technologies, autonomous systems, optical sensors, and digital engineering solutions. The company was founded in 2020 and is headquartered in Jacksonville, FL.

Redwire Corporation

Redwire Corp

Redwire Corporation is seeing significant market momentum driven by record revenue growth and a substantial expansion in its contracted backlog. Community discussions are highly bullish, with investors actively debating the potential for a short squeeze and long-term valuation re-rating as the company gains traction in the space infrastructure and defense sectors.

Archer Aviation, Inc. engages in the development of electric vertical take-off and landing (eVTOL) aircraft. The company was founded by Brett Adcock and Adam Goldstein on October 16, 2018, and is headquartered in San Jose, CA.

Archer Aviation Inc - Ordinary Shares - Class A

Archer Aviation Inc

Archer Aviation is experiencing significant momentum as investors react to the company's major deal with Boeing, which involves acquiring Wisk Aero, SkyGrid, and Insitu, effectively positioning Archer as a broader player in aerospace and defense. The community is heavily focused on this strategic pivot, debating the long-term potential of these new revenue streams against concerns over cash burn and share dilution ahead of the company's upcoming earnings report.

Hims & Hers Health, Inc. operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.

Hims & Hers Health Inc - Ordinary Shares - Class A

Hims & Hers Health Inc

Hims & Hers is trending as investors weigh strong subscriber growth and international expansion against margin pressure and regulatory headlines. The community remains deeply divided, with bulls pointing to the company's long-term growth potential and share buyback program, while skeptics focus on valuation concerns and recent earnings-related volatility.

Babcock & Wilcox Enterprises, Inc. engages in the provision of fossil and renewable power generation and environmental equipment. It operates through the B&W segment. The company was founded by George H. Babcock, Stephen Wilcox, Jr., and Joseph P. Manton in 1856 and is headquartered in Akron, OH.

Babcock & Wilcox Enterprises Inc

Babcock & Wilcox is trending following strong quarterly results, with investors focusing on a rapidly expanding multi-billion dollar backlog driven by AI data center and power infrastructure demand. The community is actively discussing the stock's long-term growth potential and recent institutional activity, despite lingering volatility from short-selling pressure.

SPDR Gold Trust - SPDR Gold Shares

SPDR Gold Shares ETF

GLD is trending as traders analyze weakening U.S. labor data and potential shifts in interest rate expectations, fueling community debate over whether the asset is staging a breakout or forming a bull trap. Market participants remain focused on its technical performance relative to key support levels and broader geopolitical tensions, with many using the ETF as a hedge against currency uncertainty.

Moonlake Immunotherapeutics operates as a clinical-stage biotechnology company. It offers tri-specific Nanobody, Sonelokimab to address significant unmet needs in inflammatory skin and joint diseases. The company was founded by Kristian Reich, Jorge Santos da Silva, and Arnout Ploos van Amstel in 2021 and is headquartered in Zug, Switzerland.

MoonLake Immunotherapeutics - Ordinary Shares - Class A

MoonLake Immunotherapeutics

MoonLake Immunotherapeutics is facing intense community scrutiny and price volatility following mixed clinical trial results and subsequent financing filings, with shareholders actively debating whether recent shelf offerings signal necessary capital flexibility for commercialization or premature dilution. Investors remain focused on the company's long-term potential as a multi-indication franchise while heavily monitoring upcoming trial readouts and potential M&A activity for further catalysts.

Chainlink is the industry-standard decentralized oracle network that solves the "oracle problem" by connecting smart contracts with real-world data. Blockchains cannot access external information on their own, so Chainlink acts as a secure bridge, enabling smart contracts to react to real-world events using verified, tamper-proof data. It is widely considered one of the first decentralized oracle networks and is the market leader in bringing off-chain data on-chain.  The platform operates through a decentralized network of nodes that fetch, validate, and deliver data to smart contracts. When a contract requests information like a stock price, a committee of independent nodes retrieves and aggregates the data to reach consensus, then delivers a single trustworthy answer. Chainlink offers a suite of services including Data Feeds for asset prices, CCIP for cross-chain token transfers and messaging, Automation for triggering smart contract functions, and Proof of Reserve for verifying asset collateralization.  Chainlink has established itself as critical infrastructure for both DeFi and institutional adoption, with partnerships including Swift, Euroclear, Mastercard, UBS, ANZ, Fidelity International, and J.P. Morgan. Its institutional products include the Chainlink Runtime Environment for tokenized asset workflows, Confidential Compute for privacy-preserving computation, and the Automated Compliance Engine for embedding regulatory rules into smart contracts.  The LINK token is the native asset used to pay node operators for services, fund subscription accounts, and incentivize network security through staking. Node operators stake LINK as collateral, which can be slashed if they provide inaccurate data. Chainlink was co-founded in 2017 by Sergey Nazarov and Steve Ellis, who co-authored the white paper with Ari Juels, and raised $32 million in its September 2017 ICO.

ChainLink

Chainlink is seeing heightened community discussion as investors debate its role as critical infrastructure for the tokenized asset sector, with many focusing on the potential impact of the Clarity Act on institutional adoption. While some participants express frustration over price performance and tokenomics, others remain long-term bullish, viewing current levels as an accumulation phase ahead of anticipated cross-chain interoperability milestones.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Relay Therapeutics, Inc. (RLAY) Reports Q2 Loss, Lags Revenue Estimates

Relay Therapeutics (RLAY) delivered earnings and revenue surprises of 0.00% and -86.97%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

Akebia Therapeutics (AKBA) Reports Q2 Loss, Lags Revenue Estimates

Akebia Therapeutics (AKBA) delivered earnings and revenue surprises of +33.33% and -5.80%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

Shionogi & Co., Ltd. Unsponsored ADR (SGIOY) Beats Q1 Earnings Estimates

Shionogi & Co. (SGIOY) delivered earnings and revenue surprises of +100.00% and -0.58%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

Relay Therapeutics, Inc. (RLAY) Expected to Beat Earnings Estimates: Should You Buy?

Relay Therapeutics (RLAY) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

An AI Biotech Just Reported a 46% Revenue Jump and Its First Recurring Platform Contracts, as Its Pivot Starts Showing Up in the Numbers

An AI Biotech Just Reported a 46% Revenue Jump and Its First Recurring Platform Contracts, as Its Pivot Starts Showing Up in the Numbers An AI Biotech Just Reported a 46% Revenue Jump and Its First Recurring Platform Contracts, as Its Pivot Starts Showing Up in the Numbers PR Newswire NEW YORK...

Relay Therapeutics Insider Sale Tops $3 Million as Shares Surge 500% This Past Year

Key PointsThomas Catinazzo sold 187,163 shares of Common Stock for $3.18 million on June 22, 2026, at a weighted average price of around $16.97 per share...

Is Relay Therapeutics a Buy After Promising Trial Results?

Key PointsRelay had its initial public offering in 2020...

The Biotech Repricing Wave May Be Starting as Capital Pours into High-Impact Oncology Platforms

Biotech investors are once again rotating aggressively into clinical-stage growth stories as a fresh wave of capital raises, pipeline expansions, analyst initiations, and oncology breakthroughs reshapes momentum across the sector. $NTHI, $IMMX, $RLAY, $AKTX, $LIMN

Why Relay Therapeutics Stock Popped on Wednesday

Key PointsThis was aided by a pair of bullish analyst updates...

RLAY Stock Declines Pre-Market After $175M Offering — Despite Fresh Bullish Calls On Relay's Zovegalisib

Equity

Relay Therapeutics announced that it had commenced an offering of $175 million worth of shares of its common stock late Tuesday.

Relay Therapeutics, Inc. engages in transforming the drug discovery process with an initial focus on enhancing small molecule therapeutic discovery in targeted oncology. Its Dynamo platform is use to integrate an array of edge experimental and computational approaches, which allows to apply the understanding of protein structure and motion to drug discovery. The company was founded by David Elliot Shaw, Matthew P. Jacobson, Dorothee Kern, Mark Murcko, Alexis Borisy, and Jakob Loven on May 4, 2015 and is headquartered in Cambridge, MA.

Relay Therapeutics Inc

Bullish Sentiment

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Feed

News

Sentiment

Earnings

Fundamentals

Info